EyePoint (EYPT) | Financial Analysis & Statements
EyePoint Pharmaceuticals Inc. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
620.0K
Gross Profit
245.0K
39.52%
Operating Income
-70.3M
-11,345.97%
Net Income
-67.6M
-10,904.68%
EPS (Diluted)
$-0.81
Balance Sheet Metrics
Total Assets
364.0M
Total Liabilities
57.9M
Shareholders Equity
306.1M
Debt to Equity
0.19
Cash Flow Metrics
Operating Cash Flow
-71.3M
Free Cash Flow
-66.0M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
EyePoint Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 31.4M | 43.3M | 46.0M | 41.4M | 36.9M |
| Cost of Goods Sold | 2.1M | 3.7M | 4.6M | 8.3M | 8.2M |
| Gross Profit | 29.3M | 39.6M | 41.4M | 33.1M | 28.8M |
| Gross Margin % | 93.4% | 91.4% | 89.9% | 79.9% | 77.9% |
| Operating Expenses | |||||
| Research & Development | 221.0M | 132.9M | 64.7M | 49.6M | 28.5M |
| Selling, General & Administrative | 51.7M | 52.5M | 51.8M | 60.3M | 53.1M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 272.7M | 185.4M | 116.5M | 110.0M | 81.6M |
| Operating Income | -243.4M | -145.9M | -75.1M | -78.9M | -55.3M |
| Operating Margin % | -776.0% | -337.1% | -163.1% | -190.7% | -149.6% |
| Non-Operating Items | |||||
| Interest Income | 11.8M | 15.1M | 6.9M | 2.1M | 292.0K |
| Interest Expense | 33.0K | 14.0K | 1.2M | 3.2M | 5.5M |
| Other Non-Operating Income | - | - | -1.3M | -22.3M | 2.1M |
| Pre-tax Income | -231.7M | -130.8M | -70.7M | -102.3M | -58.4M |
| Income Tax | 279.0K | 90.0K | 83.0K | 0 | - |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -232.0M | -130.9M | -70.8M | -102.3M | -58.4M |
| Net Margin % | -739.4% | -302.4% | -153.8% | -247.0% | -158.1% |
| Key Metrics | |||||
| EBITDA | -229.3M | -129.2M | -67.7M | -74.4M | -52.2M |
| EPS (Basic) | $-3.17 | $-2.32 | $-1.82 | $-2.74 | $-2.03 |
| EPS (Diluted) | $-3.17 | $-2.32 | $-1.82 | $-2.74 | $-2.03 |
| Basic Shares Outstanding | 73251000 | 56298000 | 38904000 | 37317000 | 28758000 |
| Diluted Shares Outstanding | 73251000 | 56298000 | 38904000 | 37317000 | 28758000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
EyePoint Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 101.8M | 99.7M | 281.3M | 95.6M | 178.6M |
| Short-term Investments | 204.3M | 271.2M | 49.8M | 48.9M | 33.0M |
| Accounts Receivable | 651.0K | 607.0K | 805.0K | 15.5M | 18.4M |
| Inventory | 1.8M | 2.3M | 3.9M | 2.9M | 3.6M |
| Other Current Assets | 2.0M | 1.4M | 1.0M | 782.0K | 4.2M |
| Total Current Assets | 328.7M | 383.3M | 344.8M | 172.8M | 237.7M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 29.6M | 27.6M | 8.1M | 8.5M | 3.7M |
| Goodwill | - | - | - | 0 | 22.7M |
| Intangible Assets | - | - | - | - | 22.7M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 6.1M | 6.0M | 150.0K | 150.0K | 150.0K |
| Total Non-Current Assets | 35.3M | 35.2M | 10.4M | 7.5M | 25.6M |
| Total Assets | 364.0M | 418.5M | 355.2M | 180.4M | 263.4M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 10.5M | 11.7M | 6.5M | 5.9M | 7.4M |
| Short-term Debt | - | - | - | 10.5M | 782.0K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 2.1M | 1.4M | 646.0K | 579.0K | - |
| Total Current Liabilities | 37.0M | 49.0M | 63.3M | 34.5M | 23.7M |
| Non-Current Liabilities | |||||
| Long-term Debt | 20.8M | 21.9M | 4.9M | 35.3M | 38.4M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 87.0K | 205.0K | - | 600.0K | 2.4M |
| Total Non-Current Liabilities | 20.9M | 32.9M | 25.6M | 49.5M | 55.3M |
| Total Liabilities | 57.9M | 82.0M | 88.9M | 84.0M | 79.0M |
| Equity | |||||
| Common Stock | 83.0K | 68.0K | 49.0K | 34.0K | 34.0K |
| Retained Earnings | -1.1B | -873.0M | -742.1M | -671.4M | -569.1M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 306.1M | 336.5M | 266.3M | 96.4M | 184.4M |
| Key Metrics | |||||
| Total Debt | 20.8M | 21.9M | 4.9M | 45.8M | 39.2M |
| Working Capital | 291.6M | 334.3M | 281.5M | 138.3M | 214.1M |
Balance Sheet Composition
EyePoint Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -232.0M | -130.9M | -70.8M | -102.3M | -58.4M |
| Depreciation & Amortization | 2.3M | 1.5M | 464.0K | 2.4M | 2.8M |
| Stock-Based Compensation | 27.9M | 36.7M | 12.1M | 14.2M | 7.4M |
| Working Capital Changes | -38.5M | -33.5M | 57.4M | -4.2M | -10.2M |
| Operating Cash Flow | -244.8M | -132.0M | -1.7M | -90.4M | -57.8M |
| Investing Activities | |||||
| Capital Expenditures | -3.1M | -4.1M | -3.5M | -2.2M | -156.0K |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -252.0M | -398.3M | -55.1M | -139.1M | -33.0M |
| Investment Sales | 323.7M | 183.0M | 55.3M | 124.0M | 0 |
| Investing Cash Flow | 68.6M | -219.4M | -3.3M | -17.3M | -33.1M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | 0 | 5.3M | 73.9M | 0 |
| Debt Repayment | -105.0K | -105.0K | -45.8M | -71.8M | -146.0K |
| Financing Cash Flow | 171.4M | 158.0M | 173.2M | 9.4M | 216.5M |
| Free Cash Flow | -243.4M | -130.3M | -1.6M | -67.2M | -50.3M |
| Net Change in Cash | -4.8M | -193.3M | 168.2M | -98.3M | 125.6M |
Cash Flow Trend
EyePoint Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-4.34
Forward P/E
-4.92
Price to Book
3.73
Price to Sales
36.62
PEG Ratio
-0.16
Profitability Ratios
Profit Margin
93.41%
Operating Margin
-450.66%
Return on Equity
-72.19%
Return on Assets
-38.89%
Financial Health
Current Ratio
8.88
Debt to Equity
46.82
Beta
1.91
Per Share Data
EPS (TTM)
$-3.17
Book Value per Share
$3.70
Revenue per Share
$0.43
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| EYPT | 1.1B | -4.34 | 3.73 | -72.19% | 93.41% | 46.82 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Recursion | 1.9B | -2.44 | 1.64 | -59.54% | 4.45% | 6.89 |
| Capricor | 2.0B | -15.61 | 6.62 | -46.56% | 0.00% | 4.75 |
| Zymeworks | 2.0B | 3.79 | 7.32 | -26.72% | -76.56% | 6.80 |
Financial data is updated regularly. All figures are in the company's reporting currency.






